Lumos ViraDx
ViraDX is a rapid point-of-care test that simultaneously tests for acute respiratory infections caused by the COVID-19, influenza A, and influenza B viruses.
PRODUCT INFO
ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test is a lateral flow immunoassay intended for the in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, influenza A and influenza B directly from anterior nasal or nasopharyngeal swab specimens obtained from patients who are suspected of COVID-19 by their healthcare provider, within the first five days of onset of symptoms.
Benefits of using ViraDx
Efficient
1 sample - 3 results to aid in a differential diagnosis at the point-of-care
Rapid
Actionable results at 15 minutes to help improve patient management decisions during the patient visit
Instrument-Free
User-friendly test procedure for non-lab settings
Accurate
COVID-19 (Anterior nasal swab): Sensitivity 93.8%; Specificity 100%
COVID-19 (Nasopharyngeal): Sensitivity 93.1%; Specificity 100%
Flu A: Sensitivity 92.2%; Specificity 94.2%
Flu B: Sensitivity 90.0%; Specificity 94.3%
Background Information
Influenza (flu) is a highly contagious acute viral infection of the respiratory tract. It is a communicable disease easily transmitted from person to person through aerosol droplets excreted when sneezing and coughing. There are two main types of influenza - type A and type B.2
Early differential diagnosis of influenza type A or type B can allow for proper treatment. Early diagnosis and treatment are of particular value in a clinical setting where an accurate diagnosis can assist the healthcare professional with the management of influenza patients who are at risk for complications.3
COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Similar to influenza, the virus can spread from an infected person's mouth or nose ranging from larger respiratory droplets to smaller aerosols.4 COVID-19 symptoms can range from mild to severe.
As the early symptoms of COVID-19 are like those of seasonal influenza type A or B, a rapid, point- of-care test can help support the differential diagnosis of COVID-19, influenza A and B.
For in vitro diagnostic use.
For Rx use only.